原发性十二指肠癌肝转移介入治疗18例分析  

Interventional therapy in 18 patients with hepatic metastasis primary duodenal carcinoma

作　　者：远丽芳 刘俊宝 丛明华[3] 姚克青 田立霞 Yuan Lifang Liu Junbao Cong Minghua Yao Keqing Tian Lixia(Department of Medical Oncology, Huanxing Cancer Hosipital of Chaoyang Area, Beijing 100122, China z Department of Medical Oncol- ogy Chaoyang Sanhuan Cancer Hospital ,Beijing 100122, China Department of Medical Oncology, Cancer Hospital ＆ Institute, CAMS ＆ PUMC ,Beijing 100021, China.)

机构地区：[1]北京市朝阳区桓兴肿瘤医院肿瘤内科,北京100122 [2]北京市朝阳区三环肿瘤医院内七病区,北京100122 [3]中国医学科学院肿瘤医院综合科,北京100021

出　　处：《现代肿瘤医学》2016年第23期3775-3777,共3页Journal of Modern Oncology

摘　　要：目的：回顾性分析原发性十二指肠癌肝转移介入治疗的疗效,研究介入治疗的效果。方法：分析2002年1月-2012年12月原发性十二指肠癌肝转移患者18例,明确介入治疗的有效率及对生存期的影响。结果：规律栓塞化疗患者10例,有效率10%,1例PR,6例SD,3例PD;不规律栓塞化疗患者8例。全组中位生存期（OS）7.14个月,规律介入治疗组长于不规律治疗组,但无统计学意义（14.33个月vs 5.71个月,HR：0.28,95%CI：0.06~1.20,P=0.08）。结论：介入治疗可能是原发性十二指肠肝转移有效的治疗方法,值得进一步研究。Objective： To determine efficacy of interventional therapy in hepatic metastasis primary duodenal carcinoma（ PDC）. Methods： Response rates and overall survival（ OS） were analysed in 18 patients with hepatic metastasis PDC who received interventional therapy. Results： Partial response（ PR） in 10 patients regular interventional therapy was achieved in 1（ 10%）,disease stabilization（ SD） in 6,3 progressed（ PD）. 8 patients did not receive regular interventional therapy. The OS for 18 patients was 7. 14 months,and the patients who received regular interventional therapy had a longer OS（ 14. 33 months） compared with patients who did not receive regular interventional therapy（ 5. 71 months）（ HR： 0. 28,95% CI： 0. 06 ~ 1. 20,P = 0. 08）. Conclusion： Patients with hepatic metastasis primary duodenal carcinoma may be beneficial from interventional therapy.

关 键 词：原发性十二指肠癌 介入治疗 总生存 

分 类 号：R735.3[医药卫生—肿瘤]